Business Context and Reporting Period
This Form 8-K Current Report was filed by DanDrit Biotech USA, Inc. (not Lunai Bioworks Inc.) on December 31, 2014. The report discloses a material definitive agreement and the unregistered sale of equity securities to a foreign investor.
Key Financial Metrics
- Transaction Value: The Company issued and sold 400,000 shares of common stock at a price of $5.00 per share, raising a total of $2,000,000.
- Outstanding Shares: As of the filing date, there were 9,533,290 shares of Common Stock issued and outstanding.
- Commissions: No commissions were paid by the Company in connection with the sale.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the specific transaction details.
Material Changes
The primary material change is the increase in outstanding common stock by 400,000 shares following the closing of the Securities Purchase Agreement (SPA) on December 31, 2014. The shares were sold to a single foreign investor.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The transaction relied on exemptions from registration under Regulation S. The investor represented that they are not a "U.S. person," are acquiring the securities for investment purposes, and have the financial sophistication to evaluate the risks.
Investor Verification Checklist
- Verify the identity of the foreign investor and the terms of the Securities Purchase Agreement (Exhibit 10.1).
- Confirm the updated total share count and potential dilution impact on existing shareholders.
- Review the Company's use of proceeds from the $2,000,000 capital raise.
- Check for any subsequent filings regarding the registration rights or resale restrictions of the newly issued shares.